Companies

Search any private company and open it for the full read — what they raised, how they compare to peers, and who's behind it.

SectorThe company’s primary industry.
StageBased on the size of their most recent round.
CountryWhere the company is registered.
By default only operating companies show. Enable to include investment vehicles like funds and SPVs.
Reset
Sort by
CompanySectorLatest stageRaisedModeled value est.RoundsInvestors
Amgen Inc · Thousand OaksBiotechnologyGrowth/Late$4.8B$106.1B ($15.6B–$191.0B)20
Sana Biotechnology, Inc. · SEATTLE
Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.
BiotechnologyGrowth/Late$866.9M$34.8B ($5.1B–$62.7B)20
National Resilience, Inc. · La Jolla
Resilience is a biomanufacturing CDMO improving access to complex medicines, with end-to-end solutions for safe & scalable biologics manufacturing.
BiotechnologyGrowth/Late$755.0M$29.2B ($4.7B–$51.2B)10
Theranos Inc · PALO ALTOBiotechnologyGrowth/Late$627.2M$24.7B ($3.6B–$44.5B)20
Moderna Therapeutics, Inc. · CAMBRIDGEBiotechnologyGrowth/Late$451.4M$19.2B ($2.8B–$34.5B)10
Neumora Therapeutics, Inc. · WatertownBiotechnologyGrowth/Late$474.4M$19.0B ($3.0B–$33.7B)10
Allogene Therapeutics, Inc. · SOUTH SAN FRANCISCOBiotechnologyGrowth/Late$411.8M$17.5B ($2.6B–$31.5B)10
Quantrx Biomedical Corp · DOYLESTOWNBiotechnologyGrowth/Late$406.0M$17.2B ($2.5B–$31.0B)10
Sarepta Therapeutics, Inc. · CAMBRIDGEBiotechnologySeries D+$430.5M$16.5B ($1.8B–$36.1B)20
Guardant Health, Inc. · Redwood CityBiotechnologySeries D+$500.0M$13.2B ($1.5B–$28.9B)50
Inspiration Biopharmaceuticals Inc · LAGUNA NIGUELBiotechnologySeries D+$461.3M$10.2B ($1.1B–$22.4B)40
Intarcia Therapeutics, Inc · Boston
ABOUT US – Intarcia Life Sciences
BiotechnologyGrowth/Late$1.2B$8.4B ($1.2B–$15.2B)100
Asklepios BioPharmaceutical, Inc. · DURHAMBiotechnologySeries D+$199.7M$8.2B ($905.4M–$18.0B)10
Adaptive Biotechnologies Corp · SEATTLEBiotechnologySeries D+$614.0M$8.0B ($884.5M–$17.6B)90
Affinivax, Inc. · CAMBRIDGEBiotechnologySeries D+$233.0M$7.8B ($1.0B–$16.2B)20
Areteia Therapeutics, Inc. · CHAPEL HILLBiotechnologySeries D+$360.0M$7.8B ($1.6B–$13.6B)10
ImmunityBio, Inc. · SAN DIEGO
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
BiotechnologyGrowth/Late$640.1M$7.8B ($2.9B–$10.6B)80
Sonoma Biotherapeutics, Inc. · SOUTH SAN FRANCISCOBiotechnologySeries D+$265.0M$7.7B ($1.2B–$14.9B)10
GIO World Health Ltd · LONDONBiotechnologySeries D+$300.0M$7.4B ($1.4B–$13.6B)10
Micromet, Inc. · RockvilleBiotechnologySeries D+$175.5M$7.2B ($795.4M–$15.8B)10
Denali Therapeutics Inc. · SOUTH SAN FRANCISCOBiotechnologyGrowth/Late$499.7M$7.2B ($3.1B–$9.5B)10
Instil Bio, Inc. · DALLASBiotechnologySeries D+$381.2M$6.5B ($840.7M–$13.4B)40
Neuralink Corp. · FREMONT
Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.
BiotechnologyGrowth/Late$1.2B$6.4B ($4.0B–$7.6B)50
Umoja Biopharma, Inc. · SEATTLEBiotechnologySeries D+$210.0M$6.3B ($951.9M–$12.5B)10
Humacyte, Inc. · DURHAMBiotechnologySeries D+$274.8M$6.2B ($680.0M–$13.5B)30
NiKang Therapeutics, Inc. · WilmingtonBiotechnologySeries D+$200.0M$6.2B ($906.7M–$12.2B)10
BioMotiv, LLC · CLEVELANDBiotechnologySeries D+$145.7M$6.0B ($660.6M–$13.2B)10
Insitro, Inc. · South San FranciscoBiotechnologySeries D+$143.2M$5.9B ($649.2M–$12.9B)10
Avidity Biosciences, Inc. · San DiegoBiotechnologyGrowth/Late$527.8M$5.7B ($2.5B–$7.5B)40
Arbor Biotechnologies, Inc. · CAMBRIDGEBiotechnologySeries D+$230.6M$5.7B ($974.7M–$10.8B)20
VelosBio Inc. · BelmontBiotechnologySeries D+$210.5M$5.6B ($621.1M–$12.3B)40
Erasca, Inc. · San DiegoBiotechnologySeries D+$183.7M$5.2B ($568.5M–$11.3B)20
Aerie Pharmaceuticals Inc · BedminsterBiotechnologySeries D+$189.6M$5.2B ($566.7M–$11.3B)50
Atreca, Inc. · REDWOOD CITYBiotechnologySeries D+$222.2M$5.2B ($566.7M–$11.3B)80
Allovir, Inc. · HoustonBiotechnologySeries D+$151.3M$5.0B ($549.7M–$11.0B)20
Venn Biosciences Corp · SOUTH SAN FRANCISCOBiotechnologySeries D+$214.6M$5.0B ($786.0M–$9.6B)30
Editas Medicine, Inc. · CAMBRIDGEBiotechnologySeries D+$120.0M$4.9B ($544.0M–$10.8B)10
Graphite Bio, Inc. · SOUTH SAN FRANCISCOBiotechnologySeries D+$150.7M$4.9B ($683.4M–$10.0B)10
Gyroscope Therapeutics Ltd · STEVENAGE, HERTFORDSHIREBiotechnologySeries D+$148.0M$4.8B ($670.9M–$9.6B)10
Semma Therapeutics, Inc. · CAMBRIDGEBiotechnologySeries D+$129.3M$4.7B ($516.2M–$10.3B)20
Dyne Therapeutics, Inc. · WALTHAMBiotechnologySeries D+$115.7M$4.6B ($524.5M–$10.0B)10
Generation Bio Co. · CAMBRIDGEBiotechnologySeries D+$211.8M$4.6B ($505.3M–$10.1B)20
Imvax, Inc. · PHILADELPHIABiotechnologySeries D+$151.8M$4.6B ($509.4M–$10.0B)30
Chinook Therapeutics U.S., Inc. · SEATTLEBiotechnologySeries D+$180.0M$4.5B ($521.3M–$9.8B)20
Braeburn Pharmaceuticals, Inc. · PRINCETONBiotechnologySeries D+$110.0M$4.5B ($498.7M–$9.9B)10
SutroVax, Inc. · FOSTER CITYBiotechnologySeries D+$205.9M$4.5B ($498.7M–$9.9B)40
Vividion Therapeutics, Inc. · SAN DIEGOBiotechnologySeries D+$240.7M$4.5B ($612.0M–$9.2B)40
Cytek BioSciences, Inc. · FREMONTBiotechnologySeries D+$120.0M$4.5B ($544.0M–$9.4B)10
Schrodinger, Inc. · NEW YORKBiotechnologySeries D+$159.8M$4.4B ($488.8M–$9.7B)40
Atea Pharmaceuticals, Inc. · BOSTONBiotechnologySeries D+$175.9M$4.4B ($487.3M–$9.7B)40
Talaris Therapeutics, Inc. · LOUISVILLEBiotechnologySeries D+$115.0M$4.4B ($521.3M–$9.4B)10
Synthego Corp · REDWOOD CITYBiotechnologySeries D+$155.7M$4.4B ($481.8M–$9.6B)50
Neon Therapeutics, Inc. · CAMBRIDGEBiotechnologySeries D+$106.0M$4.4B ($480.5M–$9.6B)10
Ngm Biopharmaceuticals Inc · SOUTH SAN FRANCISCOBiotechnologySeries D+$341.3M$4.4B ($480.5M–$9.6B)100
JW (Cayman) Therapeutics Co. Ltd · ShanghaiBiotechnologySeries D+$105.5M$4.4B ($478.5M–$9.5B)10
Akouos, Inc. · BostonBiotechnologySeries D+$137.7M$4.3B ($476.3M–$9.5B)30
Kronos Bio, Inc. · San MateoBiotechnologySeries D+$123.0M$4.3B ($476.0M–$9.5B)20
Crinetics Pharmaceuticals, Inc. · SAN DIEGOBiotechnologySeries D+$428.0M$4.3B ($1.6B–$6.2B)30
Neogene Therapeutics, Inc. · New YorkBiotechnologySeries D+$125.0M$4.3B ($498.7M–$9.2B)20
Adaptimmune Ltd · ABINGDON, OXFORDSHIREBiotechnologySeries D+$103.8M$4.3B ($470.6M–$9.4B)10
Unum Therapeutics Inc. · CAMBRIDGEBiotechnologySeries D+$220.5M$4.3B ($473.3M–$9.3B)40
Rubius Therapeutics, Inc. · CAMBRIDGEBiotechnologySeries D+$216.2M$4.2B ($458.8M–$9.1B)20
Sangart Inc · SAN DIEGOBiotechnologySeries D+$165.9M$4.2B ($456.8M–$9.1B)30
Pliant Therapeutics, Inc. · SOUTH SAN FRANCISCOBiotechnologySeries D+$162.6M$4.1B ($455.4M–$9.1B)20
Allakos Inc. · SAN CARLOSBiotechnologySeries D+$128.1M$4.1B ($454.0M–$9.0B)20
Antigenics LLC/DE · LEXINGTONBiotechnologySeries C$100.0M$4.1B ($309.3M–$10.8B)10
Genesis Biopharma, Inc · WOODLAND HILLSBiotechnologySeries C$131.5M$4.1B ($309.3M–$10.8B)80
Stem Biotech LLC · KENNESAWBiotechnologySeries C$100.0M$4.1B ($309.3M–$10.8B)10
Alder Biopharmaceuticals Inc · BOTHELLBiotechnologySeries C$100.0M$4.1B ($309.3M–$10.8B)10
AbSci Corp · VANCOUVERBiotechnologySeries D+$221.0M$4.1B ($566.7M–$8.2B)50
Nutcracker Therapeutics, Inc. · EMERYVILLEBiotechnologySeries D+$172.5M$4.1B ($655.1M–$7.8B)40
Kyverna Therapeutics, Inc. · EMERYVILLEBiotechnologySeries D+$152.0M$4.0B ($689.1M–$7.5B)10
Artiva Biotherapeutics, Inc. · San DiegoBiotechnologySeries D+$163.4M$4.0B ($544.0M–$8.1B)20
2seventy bio, Inc. · CAMBRIDGEBiotechnologySeries D+$170.0M$4.0B ($770.7M–$7.2B)10
Janux Therapeutics, Inc. · La JollaBiotechnologySeries D+$192.4M$4.0B ($566.7M–$8.0B)30
Kinnate Biopharma Inc. · SAN DIEGOBiotechnologySeries C$172.5M$3.9B ($303.1M–$10.3B)20
CinCor Pharma, Inc. · CINCINNATIBiotechnologySeries D+$142.9M$3.9B ($647.7M–$7.5B)10
Bloem Life Enterprise, Inc. · HOUSTONBiotechnologySeries D+$145.0M$3.9B ($657.3M–$7.4B)10
Palleon Pharmaceuticals Inc. · WALTHAMBiotechnologySeries D+$120.6M$3.9B ($453.3M–$8.4B)20
Amunix Pharmaceuticals, Inc. · SOUTH SAN FRANCISCOBiotechnologySeries D+$203.9M$3.9B ($530.4M–$7.9B)40
Arcutis Biotherapeutics, Inc. · WESTLAKE VILLAGEBiotechnologySeries C$94.5M$3.9B ($292.3M–$10.2B)10
Ideaya Biosciences, Inc. · South San FranciscoBiotechnologySeries C$111.4M$3.9B ($290.8M–$10.1B)20
Neurelis, Inc. · SAN DIEGOBiotechnologySeries D+$221.8M$3.8B ($520.2M–$7.7B)80
Flame Biosciences, Inc. · NEW YORKBiotechnologySeries D+$108.5M$3.8B ($453.3M–$8.1B)20
Caribou Biosciences, Inc. · BERKELEYBiotechnologySeries D+$141.0M$3.8B ($521.3M–$7.7B)30
Eikon Therapeutics, Inc. · HAYWARDBiotechnologyGrowth/Late$1.1B$3.8B ($2.2B–$4.6B)40
Forge Biologics Holdings, LLC · GROVE CITYBiotechnologySeries D+$160.0M$3.8B ($544.0M–$7.5B)20
Shoreline Biosciences, Inc. · San DiegoBiotechnologySeries D+$186.0M$3.7B ($634.7M–$7.0B)30
GIO World Health (Europe) Ltd · LONDONBiotechnologySeries D+$150.0M$3.7B ($680.0M–$6.8B)10
Gio World Health (Europe) Sa · PARISBiotechnologySeries D+$150.0M$3.7B ($680.0M–$6.8B)10
Stoke Therapeutics, Inc. · BedfordBiotechnologySeries C$90.8M$3.7B ($278.4M–$9.7B)20
4D Molecular Therapeutics Inc · EMERYVILLEBiotechnologySeries C$108.6M$3.7B ($278.4M–$9.7B)30
DNA Research INST LLC · WEST PALM BEACHBiotechnologySeries C$94.5M$3.7B ($292.3M–$9.5B)10
M3 Biotechnology, Inc. · SEATTLEBiotechnologySeries C$107.3M$3.6B ($275.3M–$9.6B)40
Iterative Scopes, Inc. · CambridgeBiotechnologySeries D+$172.1M$3.6B ($634.7M–$6.7B)20
Arsenal Biosciences, Inc. · South San FranciscoBiotechnologySeries D+$579.2M$3.5B ($1.5B–$4.9B)30
Sequenom Inc · SAN DIEGOBiotechnologySeries D+$268.1M$3.5B ($385.3M–$7.7B)40
Sutro Biopharma Inc · SOUTH SAN FRANCISCOBiotechnologySeries C$85.4M$3.5B ($264.1M–$9.2B)10
Checkmate Pharmaceuticals, Inc. · CAMBRIDGEBiotechnologySeries C$185.1M$3.5B ($263.2M–$9.2B)60
Black Diamond Therapeutics, Inc. · CAMBRIDGEBiotechnologySeries C$146.3M$3.5B ($262.9M–$9.2B)40